Rubius Therapeutics Stock EBITDA
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Rubius Therapeutics fundamentals help investors to digest information that contributes to Rubius Therapeutics' financial success or failures. It also enables traders to predict the movement of Rubius Pink Sheet. The fundamental analysis module provides a way to measure Rubius Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rubius Therapeutics pink sheet.
Rubius |
Rubius Therapeutics Company EBITDA Analysis
Rubius Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Rubius Therapeutics EBITDA | (169.55 M) |
Most of Rubius Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rubius Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Rubius Therapeutics reported earnings before interest,tax, depreciation and amortization of (169.55 Million). This is 119.32% lower than that of the Biotechnology sector and 269.29% lower than that of the Health Care industry. The ebitda for all United States stocks is 104.35% higher than that of the company.
Rubius EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rubius Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rubius Therapeutics could also be used in its relative valuation, which is a method of valuing Rubius Therapeutics by comparing valuation metrics of similar companies.Rubius Therapeutics is currently under evaluation in ebitda category among its peers.
Rubius Fundamentals
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 | |||
| Current Valuation | 22.18 M | |||
| Shares Outstanding | 90.4 M | |||
| Shares Owned By Insiders | 5.55 % | |||
| Shares Owned By Institutions | 72.61 % | |||
| Number Of Shares Shorted | 1.53 M | |||
| Price To Book | 0.42 X | |||
| EBITDA | (169.55 M) | |||
| Net Income | (179.67 M) | |||
| Cash And Equivalents | 140.71 M | |||
| Cash Per Share | 1.56 X | |||
| Total Debt | 76.15 M | |||
| Debt To Equity | 1.17 % | |||
| Current Ratio | 4.63 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (150.14 M) | |||
| Short Ratio | 0.49 X | |||
| Earnings Per Share | (2.27) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 20 | |||
| Beta | 2.45 | |||
| Market Capitalization | 7.5 M | |||
| Total Asset | 23.07 M | |||
| Z Score | -23.1 | |||
| Net Asset | 23.07 M |
About Rubius Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rubius Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rubius Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rubius Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |